Physician profile
Kelly Mitchell
NPI 1174291058
$4,112.57
in general payments reported to CMS, 2019-2025
30 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.12 · 2023: $583 · 2024: $2,383 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578 · Honoraria: $632 · Consulting Fee: $555 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.55 |
| Honoraria | $632.00 |
| Consulting Fee | $555.00 |
| Education | $288.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $813.61 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $754.08 | 2023-2025 | |
| Pharmaessentia USA Corporation | $353.57 | 2023-2025 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $289.85 | 2023-2025 | Iclusig |
| Incyte Corporation | $281.40 | 2023-2025 | Jakafi |
| Taiho Oncology, INC. | $265.04 | 2023-2025 | |
| Abbvie INC. | $203.85 | 2024-2025 | |
| Geron Corporation | $164.20 | 2024-2025 | Rytelo |
| Daiichi Sankyo INC. | $154.58 | 2022-2025 | Vanflyta, Injectafer |
| Astellas Pharma US INC | $94.70 | 2023-2025 | Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $80.69 | 2025 | Reblozyl |
| Adaptive Biotechnologies Corporation | $75.73 | 2023-2025 | Clonoseq |
| Glaxosmithkline, LLC. | $57.46 | 2024-2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $53.73 | 2023-2025 | Keytruda, Prevymis, Keytruda Qlex |
| Sobi, INC | $52.30 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $51.21 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $50.89 | 2023-2024 | Imfinzi |
| Cti Biopharma Corp. | $42.53 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $35.81 | 2025 | Pyrukynd |
| Autolus INC | $34.77 | 2025 | |
| Celgene Corporation | $33.59 | 2024-2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $32.95 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $26.15 | 2022-2023 | Imbruvica, Epkinly |
| Servier Pharmaceuticals LLC | $18.16 | 2025 | |
| Beone Medicines USA, INC. | $16.43 | 2025 | Brukinsa |
| Genmab U.S., INC. | $16.31 | 2025 | Epkinly |
| Stemline Therapeutics INC. | $15.58 | 2025 | Elzonris |
| Sanofi-Aventis U.S. LLC | $15.08 | 2024 | |
| Immunocore Limited | $14.41 | 2024 | Kimmtrak |
| Syndax Pharmaceuticals, INC. | $13.91 | 2025 | Niktimvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.